Cucciare Michael A, Hagedorn Hildi J, Bounthavong Mark, Abraham Traci H, Greene Carolyn J, Han Xiaotong, Kemp Lakiesha, Marchant Kathy, White Penny, Humphreys Keith
Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, AR, 72205, USA.
Veterans Affairs South Central Mental Illness Research, Education and Clinical Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR, 72205, USA.
Contemp Clin Trials Commun. 2022 Sep 5;29:100994. doi: 10.1016/j.conctc.2022.100994. eCollection 2022 Oct.
Long-term benzodiazepine dependence carries significant health risks which might be reduced with low-cost patient self-management interventions. A booklet version of one such intervention (Eliminating Medications Through Patient Ownership of End Results; EMPOWER) proved effective in a Canadian clinical trial with older adults. Digitizing such an intervention for electronic delivery and tailoring it to different populations could expand its reach. Accordingly, this article describes the protocol for a randomized controlled trial to test the effectiveness of an electronically-delivered, direct-to-patient benzodiazepine cessation intervention tailored to U.S. military veterans.
Design: Two-arm individually randomized controlled trial.
US Veterans Health Administration primary care clinics.
Primary care patients taking benzodiazepines for three or more months and having access to a smartphone, tablet or desktop computer.
Participants will be randomized to receive either the electronically-delivered EMPOWER (EMPOWER-ED) protocol or asked to continue to follow provider recommendations regarding their benzodiazepine use (treatment-as-usual).
The primary outcomes are complete benzodiazepine cessation and 25% dose reduction, assessed using administrative and self-report data, between baseline and six-month follow-up. Secondary outcomes are self-reported anxiety symptoms, sleep quality, and overall health and quality of life, measured at baseline and 6-month follow-up, and benzodiazepine cessation at 12-month follow-up.
This randomized controlled trial will evaluate whether the accessibility and effectiveness of a promising intervention for benzodiazepine cessation can be improved through digitization and population tailoring.
长期使用苯二氮䓬类药物会带来重大健康风险,而低成本的患者自我管理干预措施可能会降低这些风险。在一项针对老年人的加拿大临床试验中,一种此类干预措施的手册版本(通过患者对最终结果的掌控消除药物;EMPOWER)被证明是有效的。将这种干预措施数字化以便电子交付并针对不同人群进行调整,可以扩大其覆盖范围。因此,本文描述了一项随机对照试验的方案,以测试一种专门为美国退伍军人量身定制的、通过电子方式直接提供给患者的苯二氮䓬类药物戒断干预措施的有效性。
设计:双臂个体随机对照试验。
美国退伍军人健康管理局初级保健诊所。
服用苯二氮䓬类药物三个月或更长时间且能够使用智能手机、平板电脑或台式电脑的初级保健患者。
参与者将被随机分配接受电子交付的EMPOWER(EMPOWER-ED)方案,或被要求继续遵循提供者关于其苯二氮䓬类药物使用的建议(常规治疗)。
主要结局是在基线和六个月随访之间,使用行政和自我报告数据评估的完全停用苯二氮䓬类药物和剂量减少25%。次要结局是在基线和6个月随访时自我报告的焦虑症状、睡眠质量以及总体健康和生活质量,以及在12个月随访时的苯二氮䓬类药物戒断情况。
这项随机对照试验将评估一种有前景的苯二氮䓬类药物戒断干预措施的可及性和有效性是否可以通过数字化和针对特定人群进行调整而得到改善。